Biotechnology

As its novel oral antiviral for the 'winter vomiting bug' enters a pivotal human study, Cocrystal Pharma balances hope with financial prudence.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

A key U.S. patent extends protection for a promising CRPS-1 drug, paving the way for a potential first-in-class treatment for the debilitating condition.

Longhorn Diagnostics unveils LHNVD-501, a novel antibody targeting a universal bacterial component, offering a new front against AMR and chronic inflammation.

A new partnership provides early access to an investigational drug for FAP, offering a potential non-surgical therapeutic option for the first time.

Following its major merger with SubjectWell, Clariness unveils a new CEO and executive team, signaling a push to dominate the patient recruitment market.

As AI reshapes discovery, a new tool helps biotech and pharma firms see if they are visible in AI search results, tackling a critical new blind spot.

The pharma giant expands its collaboration with OpenProtein.AI, integrating advanced AI to accelerate the creation of new drugs for cancer and autoimmune diseases.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

With promising early data and a unique brain delivery method, AviadoBio's AVB-101 trial offers new hope for patients with FTD-GRN, a devastating disease.

The neurotech pioneer reports strong sales for its spinal cord injury therapy, secures key FDA approvals, and plans for major US stock market entry.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

Sangamo pushes a promising Fabry disease therapy toward the FDA while a cash crunch forces a strategic pivot to brain-targeting neurological cures.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

Formerly Asha Therapeutics, the biotech rebrands with top talent and an AI platform that designs novel medicines from scratch for humanity's toughest diseases.

Shanghai names Sanyou Bio a top municipal tech center, validating its AI-powered antibody library that's reshaping global drug R&D and fueling regional innovation.

The biotech firm's oversubscribed funding round will accelerate its universal flu shot and a diverse pipeline targeting cancer, malaria, and Alzheimer's.

Danish firm Evaxion, backed by the Gates Foundation, uses its AI platform to design a next-gen polio vaccine, aiming to end the disease for good.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

German CDMO Vetter wins a prestigious, client-voted award, underscoring its pivotal role and massive €2 billion investment in the world of injectable biologics.